Last-Chance cell therapy offered when standard drug fails quality checks
NCT ID NCT04400591
Summary
This program provides access to a non-standard version of a personalized cell therapy (lisocabtagene maraleucel) for adults with a type of aggressive lymphoma. It is for patients who were already prescribed this therapy, but the specific batch made for them did not pass all standard quality tests. Doctors may offer this non-standard version if they believe its potential benefit outweighs the risks for a patient who cannot wait for a new batch to be made.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.